Qualitative Concept – Page 31

DOGE terminates leases for 30 FDA sites across 23 states

6 months ago talkbio0Tagged Clinical action, DOGE, Government, leases, Site, United States Food and Drug Administration

DOGE, United States Food and Drug Administration, Site, United States Food and Drug Administration, Clinical action, Government, leases

Oncology Market in 2025: Innovation, Growth, and Patient-Centric Care

6 months ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Biosimilars, Clinical Trial Design, Combined, Immunotherapy for cancer, Neoplasms, Personalized cancer care, Precision Medicine, targeted therapies

Cancer immunotherapy, Targeted therapies , Precision medicine, AI in oncology, Combination treatments, Biosimilars, Clinical trial design, Personalized cancer care

Australia steadfast on rejection of Eisai, Biogen’s Alzheimer’s therapy Leqembi

6 months ago talkbio0Tagged Alzheimer 's disease, Australia, Decision, Eisai, Lecanemab, Leqembi, Presenile dementia

Lecanemab, Eisai, Leqembi, Alzheimer ‘s disease, Decision, Presenile dementia, Australia

The Perfect Storm: Why 2025 Will Be the Year of GxP AI in Pharma

6 months ago talkbio0Tagged Administration occupational activities, Aortic Valve Insufficiency, data-driven innovation, Drug Development, GxP, pharmaceutical manufacturing, Quality, regulatory

GxP AI, pharmaceutical manufacturing, regulatory compliance, data-driven innovation, quality management, drug development

Eikon pulls in $351M as lead drug begins Phase III journey

7 months ago talkbio0

Eikon Therapeutics Secures $351M Funding for Cancer Drug Development Eikon Therapeutics raised $351 million in a Series D funding round124 Total funding raised since 2019 launch now exceeds $1.1 billion1 Lead drug EIK1001 has entered Phase III trials for advanced melanoma14 Clinical studies ongoing in 28 countries across 5 continents14 ## Pipeline Highlights: EIK1001: TLR7/8 […]

Merck & Co. predicts Keytruda will undergo IRA price cuts before patent cliff

7 months ago talkbio0Tagged Impact food supplement, IRA, Keytruda, Merck, Patent Cliff, Prices, Sales - occupational activity, U.S.

Merck, Keytruda, Prices, IRA, Sales – occupational activity, patent cliff, Impact food supplement, U.S., Keytruda

Eikon pulls in $351M as lead drugs begins Phase III journey

7 months ago talkbio0

Eikon Therapeutics Secures $350.7 Million Series D to Advance Cancer Drug Pipeline Eikon Therapeutics, a pivotal-stage biotechnology company, has raised $350.7 million in a Series D financing round to support its clinical-stage programs and future pipeline development147. This significant funding brings Eikon’s total capital raised since its founding in 2019 to over $1.1 billion17. ## […]

FDA updates Boston Scientific’s Accolade pacemaker recall, reporting 832 injuries

7 months ago talkbio0Tagged Artificial cardiac pacemaker, Medical Devices, Mental Recall, Preventive monitoring, trauma qualifier, United States Food and Drug Administration

United States Food and Drug Administration, Mental Recall, Preventive monitoring, trauma qualifier, Medical Devices, Artificial cardiac pacemaker

Beyond the Diagnosis: Embracing the Humanity Behind Epilepsy Care

7 months ago talkbio0Tagged Comprehensive, Empowered, Epilepsy, Experience, Holistic epilepsy management, Interdisciplinary Studies, Patient-Centered, Quality of life

Patient-centered epilepsy care, Holistic epilepsy management, Quality of life in epilepsy, Empowering epilepsy patients, Multidisciplinary epilepsy treatment, Epilepsy patient experiences, Comprehensive epilepsy support